Dentulu, a teledentistry platform that offers remote dental services, has announced a collaboration with Viome, a company specializing in RNA-based health diagnostics. This partnership will make Viome’s FDA-designated CancerDetect® Salivary Diagnostic Test available through Dentulu’s provider network, with the goal of supporting earlier detection of oral and throat cancers.
According to projections for 2025, oral and pharyngeal cancers are expected to result in approximately 60,000 new cases and 13,000 deaths in the United States annually. While these cancers are typically identified during routine dental examinations, visual inspection methods often miss early-stage disease and can vary based on clinical experience. The partnership seeks to address these diagnostic limitations by introducing a molecular approach to screening.
Viome’s CancerDetect® test utilizes RNA sequencing and machine learning to identify molecular biomarkers in saliva that are associated with oral and throat cancers, including squamous cell carcinomas—the most common form of oral cancer. The test is designed to be non-invasive and administered at home, with laboratory analysis conducted by Viome.
“Dentistry is no longer simply about cleanings and cavities. It’s becoming a critical frontline in overall health and wellness,” said Dr. Arash Hakhamian, CEO of Dentulu. “Through our partnership with Viome, we are taking bold steps to bridge the gap between oral and systemic health, providing dental professionals and patients with a game-changing saliva test that can detect oral cancer early and save lives.”
“At Viome, our mission is to detect and prevent diseases like oral and throat cancer through cutting-edge RNA-based science and home-based diagnostics,” said Naveen Jain, Founder and CEO of Viome. “This collaboration with Dentulu empowers dental professionals to play a life-saving role in the early detection of oral cancers, transforming the standard of care in oral health by enabling patients to act before they become death sentences.”
Following test completion, Dentulu’s affiliated providers are positioned to guide patients through interpretation of the results and determine appropriate follow-up care. For individuals with concerning findings, referrals to local dental or medical professionals are facilitated to ensure continuity of care.
“Our technology fundamentally changes how we approach oral cancer screening,” said Dr. Edward Zuckerberg, Chief Dental Officer at Viome. “Instead of hoping to catch cancer during routine exams, we can now hunt for it at the molecular level before any visible symptoms appear. Through Dentulu's Teledentistry network, this innovative screening becomes widely accessible to patients regardless of their geographic location, bringing advanced cancer detection to both urban and remote communities.”
This development aligns with broader trends in oral-systemic health integration and may support dental professionals in expanding their role in preventive health.
For more information on Dentulu’s partnership with Viome and to access the CancerDetect Test, visit www.dentulu.com.
